Abstract: A system and method for correcting inhomogeneity of spatial intensity in 3D MR image data includes application of a 3D filter to the 3D MR image to generate a first set of data and a second set of data. The first set of data includes a high frequency component and a weak edge component, and the second set of data includes a low frequency component and a strong edge component. The system and method also include derivation of an inhomogeneity correction from the second set of data, application the inhomogeneity correction to the second set of data, and addition of the first set of data to the inhomogeneity corrected second set of data to create a corrected 3D MR image.

Abstract: A system, method, and apparatus includes a computer readable storage medium with a computer program stored thereon having instructions that cause a computer to access a first anatomical image data set of an imaging subject acquired via a morphological imaging modality, access a functional image data set of the imaging subject acquired via a functional imaging modality, register the first anatomical image data set to the functional image data set, segment the functional image data set based on the functional image data set, define a binary mask based on the segmented functional image data set, and apply the binary mask to the first anatomical image data set to construct a second anatomical image data set and an image based thereon. The second anatomical image data set is substantially free of image data of the first anatomical image data set correlating to an area outside the region of physiological activity.

Abstract: Certain examples provide systems and methods for holistic viewing to provide comparative analysis and patient treatment decision support in a drug therapy development process. A computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic decision support. In addition, the inventive may also be summarized as a computer-implemented method for developing a therapeutic drug treatment plan for a patient using quantifiable comparative holistic decision support for a known disease signature corresponding to a subject medical condition of a patient.

Abstract: Certain examples provide systems and methods for holistic viewing to provide comparative analysis and decision support in a drug development process. An example of the inventive apparatus includes a standardizer to at least one of standardize and normalize data related to drug performance for a known disease signature; and a deviation analyzer to analyze said data based on at least one of a plurality of different efficacy metrics, wherein a quantified variation between a first data set of results corresponding to an identified target drug and a second data set of results corresponding to a control, wherein said first data set of results is provided for comparison with the second data set of results and the deviation therebetween is compared to the at least one efficacy metric associated with the disease signature.

Abstract: Certain examples provide systems and methods for holistic viewing to provide comparative analysis and decision support in a drug development process. An example method includes providing a first set of data corresponding to a drug of interest: providing a disease signature; providing a reference set of drug interaction data associated with the disease signature, comparing the first set of data to the reference set using a holistic analysis, and reporting the results of the comparison. An example of the apparatus includes, a standardizer to at least one of standardize and normalize drug interaction data related to a pre-selected disease signature: a deviation analyzer to compare the drug interaction data to data corresponding to a drug under review using a holistic analysis, and a reporter for reporting the output of the deviation analyzer.

Abstract: Certain examples provide systems and methods for holistic viewing to provide comparative analysis and decision support in a drug development process. A computer-implemented method for integrated comparative holistic analysis of drug development and related quantifiable patient treatment decision support for a medical condition having a known disease signature.

Abstract: A system and method for correcting inhomogeneity of spatial intensity in 3D MR image data includes application of a 3D filter to the 3D MR image to generate a first set of data and a second set of data. The first set of data includes a high frequency component and a weak edge component, and the second set of data includes a low frequency component and a strong edge component. The system and method also include derivation of an inhomogeneity correction from the second set of data, application the inhomogeneity correction to the second set of data, and addition of the first set of data to the inhomogeneity corrected second set of data to create a corrected 3D MR image.

Abstract: A system, method, and apparatus includes a computer readable storage medium with a computer program stored thereon having instructions that cause a computer to access a first anatomical image data set of an imaging subject acquired via a morphological imaging modality, access a functional image data set of the imaging subject acquired via a functional imaging modality, register the first anatomical image data set to the functional image data set, segment the functional image data set based on the functional image data set, define a binary mask based on the segmented functional image data set, and apply the binary mask to the first anatomical image data set to construct a second anatomical image data set and an image based thereon. The second anatomical image data set is substantially free of image data of the first anatomical image data set correlating to an area outside the region of physiological activity.